Skip to main content
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
54.79
+0.33 (0.61%)
Oct 22, 2024, 4:00 PM EDT - Market closed

Ultragenyx Pharmaceutical Revenue

Ultragenyx Pharmaceutical had revenue of $147.03M in the quarter ending June 30, 2024, with 35.75% growth. This brings the company's revenue in the last twelve months to $481.30M, up 19.47% year-over-year. In the year 2023, Ultragenyx Pharmaceutical had annual revenue of $434.25M with 19.52% growth.

Revenue (ttm)
$481.30M
Revenue Growth
+19.47%
P/S Ratio
9.21
Revenue / Employee
$377,197
Employees
1,276
Market Cap
5.05B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023434.25M70.92M19.52%
Dec 31, 2022363.33M11.92M3.39%
Dec 31, 2021351.41M80.38M29.66%
Dec 31, 2020271.03M167.32M161.32%
Dec 31, 2019103.71M52.22M101.41%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Option Care Health 4.59B
DENTSPLY SIRONA 3.90B
Acadia Healthcare Company 3.06B
RadNet 1.71B
Stevanato Group 1.17B
Corcept Therapeutics 569.61M
BridgeBio Pharma 219.12M
Krystal Biotech 166.23M
Revenue Rankings

RARE News

More News